Press release
Angelman Syndrome Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Treatment Outlook, and Key Companies | Neuren Pharma, Ultragenyx, Ionis, Roche,
"Angelman Syndrome Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Angelman Syndrome Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Angelman Syndrome Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing therapies in the Angelman Syndrome Market.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Angelman Syndrome treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Angelman Syndrome market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Learn More about the Clinical and Commercial Development Activities in the Angelman Syndrome Therapeutics Domain:
https://www.delveinsight.com/report-store/angelman-syndrome-pipeline-insight?utm_source=digitaljournal&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
Angelman Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule
Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/angelman-syndrome-pipeline-insight?utm_source=digitaljournal&utm_medium=pressrelease&utm_campaign=rpr
Angelman Syndrome Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Angelman Syndrome. Currently, Neuren Pharmaceuticals is leading the therapeutics market with its Angelman Syndrome drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Angelman Syndrome Therapeutics Market Include:
• Neuren Pharmaceuticals
• Ultragenyx Pharmaceutical
• Ionis Pharmaceuticals
• Roche
• GEXVal
• PTC Therapeutics
• Taysha Gene Therapies
• Ovid Therapeutics
• GeneTX Biotherapeutics, LLC
• Ultragenyx Pharmaceutical Inc
• Hoffmann-La Roche
• Ovid Therapeutics Inc.
• Biogen
And Many Others
Angelman Syndrome Emerging and Marketed Therapies Covered in the Report Include:
• GT-AS: PTC Therapeutics
• GTX-102: Ultrageny Pharmaceutical
• GXV 001: GEXVal
• NNZ-2591: Neuren Pharmaceuticals
• RG 6091: Roche
And Many More
Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/angelman-syndrome-pipeline-insight?utm_source=digitaljournal&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Angelman Syndrome Current Treatment Patterns
4. Angelman Syndrome - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Angelman Syndrome Late-Stage Products (Phase-III)
7. Angelman Syndrome Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Angelman Syndrome Discontinued Products
13. Angelman Syndrome Product Profiles
14. Angelman Syndrome Key Companies
15. Angelman Syndrome Key Products
16. Dormant and Discontinued Products
17. Angelman Syndrome Unmet Needs
18. Angelman Syndrome Future Perspectives
19. Angelman Syndrome Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/angelman-syndrome-pipeline-insight?utm_source=digitaljournal&utm_medium=pressrelease&utm_campaign=rpr
Other Trending Healthcare Reports by DelveInsight -
Bronchial Neoplasm Market
https://www.delveinsight.com/report-store/bronchial-neoplasm-market
Gastro Intestinal Bleeding Market
https://www.delveinsight.com/report-store/gastro-intestinal-bleeding-market
Orthostatic Hypotension Market
https://www.delveinsight.com/report-store/orthostatic-hypotension-market
Pars Plantis Market
https://www.delveinsight.com/report-store/pars-plantis-market
Schistosomiasis Market
https://www.delveinsight.com/report-store/schistosomiasis-market
Vulvodynia Market
https://www.delveinsight.com/report-store/vulvodynia-market
Indolent Lymphoma Market
https://www.delveinsight.com/report-store/indolent-lymphoma-market
Liver Angiosarcoma Market
https://www.delveinsight.com/report-store/liver-angiosarcoma-market
Osteochondrodysplasia Market
https://www.delveinsight.com/report-store/osteochondrodysplasia-market
Tuberous Sclerosis Complex Market
https://www.delveinsight.com/report-store/tuberous-sclerosis-complex-market
Ocular Melanoma Market
https://www.delveinsight.com/report-store/ocular-melanoma-market
Mucopolysaccharidosis I Market
https://www.delveinsight.com/report-store/mucopolysaccharidosis-i-market
Bone Resorption Market
https://www.delveinsight.com/report-store/bone-resorption-market
Hot Flashes Market
https://www.delveinsight.com/report-store/hot-flashes-market
Cryptococcosis Market
https://www.delveinsight.com/report-store/cryptococcosis-market
Gene Therapy for Ocular Rare Disease Market
https://www.delveinsight.com/report-store/gene-therapy-for-ocular-rare-disease-market
Hypersomnia Market
https://www.delveinsight.com/report-store/hypersomnia-market
CART-related Neurotoxicity (NT) Market
https://www.delveinsight.com/report-store/cart-related-neurotoxicity-nt-market
Drug Hypersensitivity Market
https://www.delveinsight.com/report-store/drug-hypersensitivity-market
Tendonitis Market
https://www.delveinsight.com/report-store/tendonitis-market
Polypoidal Choroidal Vasculopathy (PCV) Market
https://www.delveinsight.com/report-store/polypoidal-choroidal-vasculopathy-market
Secondary Hyperparathyroidism Market
https://www.delveinsight.com/report-store/secondary-hyperparathyroidism-market
Peripheral Neuritis Market
https://www.delveinsight.com/report-store/peripheral-neuritis-market
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Angelman Syndrome Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Treatment Outlook, and Key Companies | Neuren Pharma, Ultragenyx, Ionis, Roche, here
News-ID: 3057715 • Views: …
More Releases from DelveInsight Business Research LLP
Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical S …
DelveInsight's "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis…
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Cu …
DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia…
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinica …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive…
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action …
DelveInsight's "Hearing Loss Pipeline Insight" report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hthe earing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights!…
More Releases for Angelman
Angelman Syndrome Market to Set Phenomenal Growth From 2025 to 2034
Introduction
Angelman Syndrome (AS) is a rare neurogenetic disorder caused by the loss of function of the UBE3A gene on chromosome 15. It is characterized by severe developmental delays, intellectual disability, speech impairment, seizures, and distinctive behavioral traits such as frequent smiling and excitability. Affecting approximately 1 in 12,000-20,000 live births, Angelman Syndrome has historically lacked targeted treatment options, with management focused primarily on symptom relief.
However, growing research in gene therapies,…
Angelman Syndrome Market Is Booming Worldwide 2025-2032 | Roche Biogen,Ionis Pha …
According to the latest research from Coherent Market Insights, the Angelman Syndrome Market is projected to experience significant growth between 2025 and 2032. This market intelligence report offers in-depth analysis based on thorough research, highlighting current trends, financial performance, and historical data evaluation. The company profiles within the report are derived from the current performance of the Angelman Syndrome Market, considering key factors such as drivers, trends, and challenges, as…
Angelman Syndrome Treatment Market Size is expected to grow by 2034, estimates D …
Angelman Syndrome Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Angelman Syndrome Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Angelman Syndrome Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Angelman Syndrome, historical and…
Angelman Syndrome Treatment Market Size, Treatment Drugs Report 2034
Angelman Syndrome Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Angelman Syndrome Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Angelman Syndrome Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Angelman Syndrome, historical and…
Angelman Syndrome Treatment Market Size is expected to grow by 2034, estimates D …
Angelman Syndrome Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Angelman Syndrome Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Angelman Syndrome Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Angelman Syndrome, historical and…
Angelman Syndrome Market Report 2023-2033 | Industry Size, Analysis and Latest I …
Market Overview:
The 7 major Angelman syndrome markets are expected to exhibit a CAGR of 4.4% during 2023-2033.
The report offers a comprehensive analysis of the angelman syndrome market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the proportion of various therapies, and the market's performance in the seven…
